CO5070587A1 - COMBINATION THERAPY FOR MUSCLE SCHEME FRAGILITY - Google Patents
COMBINATION THERAPY FOR MUSCLE SCHEME FRAGILITYInfo
- Publication number
- CO5070587A1 CO5070587A1 CO99037622A CO99037622A CO5070587A1 CO 5070587 A1 CO5070587 A1 CO 5070587A1 CO 99037622 A CO99037622 A CO 99037622A CO 99037622 A CO99037622 A CO 99037622A CO 5070587 A1 CO5070587 A1 CO 5070587A1
- Authority
- CO
- Colombia
- Prior art keywords
- fragility
- compositions
- combination therapy
- oxo
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Esta invención se refiere a composiciones farmacéuticas de combinación y a procedimientos, que contienen (-)-cis-6-feniI-5-(4-(2-pirrolidin-1-il-etoxi)-fenil)-5, 6, 7, 8-tetrahidronaftaIén-2-oI o una de sus sales farmacéuticamente aceptables y 2-amino-N-(2-3a(R)-bencil-2-metil-3-oxo-2, 3, 3a, 4, 6, 7-hexahidro-pirazolo[4, 3-c]piridin-5-iI)-1 (R)-benciIoximetil-2-oxo-etiI)-isobutiramida o una de sus sales farmacéuticamente aceptables, a procedimientos para usar tales composiciones y a estuches que contiene tales composiciones. Las composiciones son de utilidad para tratar fragilidad musculoesquelética, incluyendo osteoporosis, fractura osteoporótica, masa ósea reducida, fragilidad y masa muscular reducida.<EMI FILE="99037622_1" ID="1" IMF=JPEG >This invention relates to combination pharmaceutical compositions and processes, which contain (-) - cis-6-pheny-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5, 6, 7, 8-tetrahydronaphthalene-2-oI or one of its pharmaceutically acceptable salts and 2-amino-N- (2-3a (R) -benzyl-2-methyl-3-oxo-2, 3, 3a, 4, 6, 7 -hexahydro-pyrazolo [4, 3-c] pyridin-5-iI) -1 (R) -benzyoxymethyl-2-oxo-etiI) -isobutyramide or a pharmaceutically acceptable salt thereof, to methods for using such compositions and to cases that It contains such compositions. The compositions are useful for treating musculoskeletal fragility, including osteoporosis, osteoporotic fracture, reduced bone mass, fragility and reduced muscle mass. <EMI FILE = "99037622_1" ID = "1" MFI = JPEG>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5070587A1 true CO5070587A1 (en) | 2001-08-28 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99037622A CO5070587A1 (en) | 1998-06-16 | 1999-06-16 | COMBINATION THERAPY FOR MUSCLE SCHEME FRAGILITY |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (en) |
| JP (1) | JP2002518326A (en) |
| KR (1) | KR20010052852A (en) |
| CN (1) | CN1301160A (en) |
| AP (1) | AP9901582A0 (en) |
| AR (1) | AR018869A1 (en) |
| AU (1) | AU4054799A (en) |
| BG (1) | BG105041A (en) |
| BR (1) | BR9911324A (en) |
| CA (1) | CA2335134A1 (en) |
| CO (1) | CO5070587A1 (en) |
| EA (1) | EA200001186A1 (en) |
| GT (1) | GT199900087A (en) |
| HN (1) | HN1999000097A (en) |
| HR (1) | HRP20000859A2 (en) |
| HU (1) | HUP0102505A3 (en) |
| ID (1) | ID27599A (en) |
| IL (1) | IL138630A0 (en) |
| IS (1) | IS5691A (en) |
| MA (1) | MA26652A1 (en) |
| NO (1) | NO20006312D0 (en) |
| OA (1) | OA11505A (en) |
| PA (1) | PA8475901A1 (en) |
| PE (1) | PE20000646A1 (en) |
| PL (1) | PL344981A1 (en) |
| SK (1) | SK18912000A3 (en) |
| TN (1) | TNSN99124A1 (en) |
| TR (1) | TR200003544T2 (en) |
| WO (1) | WO1999065486A1 (en) |
| ZA (1) | ZA993975B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360103A1 (en) * | 1999-02-08 | 2000-08-17 | Robert Sladek | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha |
| DE60124616T2 (en) | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatic cleavage of selective modulators of the estrogen receptor |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| CA2420535A1 (en) * | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/en unknown
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/en not_active Application Discontinuation
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/en unknown
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 AR ARP990102848A patent/AR018869A1/en not_active Application Discontinuation
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/en unknown
- 1999-06-16 PL PL99344981A patent/PL344981A1/en not_active Application Discontinuation
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/en active Pending
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/en unknown
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 ID IDW20002627A patent/ID27599A/en unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/en unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/en unknown
- 1999-06-16 MA MA25628A patent/MA26652A1/en unknown
- 1999-06-16 CO CO99037622A patent/CO5070587A1/en unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/en unknown
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/en unknown
- 1999-06-16 IL IL13863099A patent/IL138630A0/en unknown
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
- 1999-06-16 CN CN99806237A patent/CN1301160A/en active Pending
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Application Discontinuation
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/en not_active Application Discontinuation
- 1999-06-16 GT GT199900087A patent/GT199900087A/en unknown
- 1999-06-16 EP EP99923802A patent/EP1087764A1/en not_active Withdrawn
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/en not_active Application Discontinuation
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/en unknown
- 2000-12-11 BG BG105041A patent/BG105041A/en unknown
- 2000-12-12 NO NO20006312A patent/NO20006312D0/en not_active Application Discontinuation
- 2000-12-14 HR HR20000859A patent/HRP20000859A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102505A3 (en) | 2002-12-28 |
| AR018869A1 (en) | 2001-12-12 |
| PE20000646A1 (en) | 2000-08-05 |
| AP9901582A0 (en) | 1999-06-30 |
| PA8475901A1 (en) | 2000-05-24 |
| ID27599A (en) | 2001-04-12 |
| KR20010052852A (en) | 2001-06-25 |
| WO1999065486A1 (en) | 1999-12-23 |
| OA11505A (en) | 2004-05-07 |
| BG105041A (en) | 2001-08-31 |
| AU4054799A (en) | 2000-01-05 |
| SK18912000A3 (en) | 2001-10-08 |
| IS5691A (en) | 2000-10-27 |
| MA26652A1 (en) | 2004-12-20 |
| HUP0102505A2 (en) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
| BR9911324A (en) | 2001-04-03 |
| NO20006312L (en) | 2000-12-12 |
| HN1999000097A (en) | 1999-11-03 |
| PL344981A1 (en) | 2001-11-19 |
| CA2335134A1 (en) | 1999-12-23 |
| NO20006312D0 (en) | 2000-12-12 |
| CN1301160A (en) | 2001-06-27 |
| EP1087764A1 (en) | 2001-04-04 |
| JP2002518326A (en) | 2002-06-25 |
| HRP20000859A2 (en) | 2001-04-30 |
| TNSN99124A1 (en) | 2005-11-10 |
| TR200003544T2 (en) | 2001-04-20 |
| ZA993975B (en) | 2000-12-15 |
| EA200001186A1 (en) | 2001-06-25 |
| GT199900087A (en) | 2000-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9714155A (en) | Prevention of bone mass loss and replacement by certain prostaglandin agonists. | |
| NO972043L (en) | Tienopyridine or thienopyrimidine derivatives and their use | |
| LU91710I2 (en) | Pazopanib, optionally in the form of a pharmaceutically acceptable salt or solvate thereof | |
| BR9813028A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| ATE329540T1 (en) | BONE PLATE FOR FIXATION OF PROXIMAL HUMERUS FRACTURES | |
| AU2001258138A1 (en) | Bone plate for the fixation of fractures of the proximal humerus | |
| SG148037A1 (en) | Fgf variants and methods for use thereof | |
| ATE250063T1 (en) | PYRAZOLOPYRIMIDINONE, CGMP PDE5 INHIBITORS, FOR THE TREATMENT OF SEXUAL DISORDERS | |
| FI945557A0 (en) | Isoxazoline compounds as anti-inflammatory agents | |
| GB0223040D0 (en) | Therapeutic compounds | |
| ZA9810735B (en) | Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use | |
| BR0105457A (en) | Therapeutic combinations to stimulate bone growth | |
| CO5070587A1 (en) | COMBINATION THERAPY FOR MUSCLE SCHEME FRAGILITY | |
| CO5070584A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES (-) - CIS-6-PHENYL-5- (4- (2-PIRROLIDIN-1-IL-ETOXI) -PENYL) -5,6,7,8-TETRAHYDRONAFTALEN -2-OL AND PARTIROID HORMONE | |
| WO2005011721A3 (en) | Use of a pak inhibitor for the treatment of a joint disease | |
| CO5070586A1 (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOESQUE-LETICA FRAGILITY | |
| WO2001080894A3 (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies | |
| HUP0202396A2 (en) | Medicaments useful for treating fractures | |
| DE60223707D1 (en) | CALCIUM-L-THREONATE FOR THE TREATMENT OF BONE FRACTURES | |
| BR0206687A (en) | Method to prevent and treat visceral pain and gastrointestinal disorders | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| GB0112494D0 (en) | New therapeutic use | |
| WO2002034280A3 (en) | Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| PT966968E (en) | THERAPEUTIC COMBINATIONS COMPREHENDING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND PROSTAGLANDINE E2 |